期刊文献+

^18F-FDG、^18F-FLT细胞结合评价肺腺癌5-Fu化疗早期反应的细胞学研究 被引量:1

An Experimental Study on the Early Changes in ^18F-FDG and ^18F-FLT Uptake on Human Lung Adenocarcinoma A-549 Cells after Chemotherapy of 5-Fu
下载PDF
导出
摘要 目的:通过测定^18F-氟代葡萄糖(FDG)和^18F-氟代胸苷(FLT)细胞结合率的变化来评估不同浓度氟尿嘧啶(5-Fu)对肺腺癌A-549细胞化疗早期反应的疗效并对两种显像剂进行初步比较。方法不同浓度(0.125、0.25、0.5、1.0 mg/mL)5-Fu 1.0 mL分别与肺腺癌A-549细胞共同孵育24 h、48 h,测定细胞对^18F-FDG和^18F-FLT的细胞结合变化并与MTT法测定的存活细胞数目和细胞抑制率比较。结果(1)5-Fu作用24 h和48 h后,^18F-FDG和^18F-FLT细胞结合率均随药物浓度的增加而下降,两者与药物浓度均呈负相关(24 h:^18F-FLT r=-0.950,P<0.01,^18F-FDG r=-0.844,P<0.01;48 h:^18F-FLT r=-0.939,P<0.01,^18F-FDG r=-0.786,P<0.01);48 h与24 h相比,两种显像剂细胞摄取率均降低;(2)24 h和48 h MTT细胞抑制率与^18F-FDG和^18F-FLT细胞结合抑制率均呈正相关(24 h:^18F-FLT r=0.897,P<0.01,^18F-FDG r=0.978,P<0.05;48 h:^18F-FLT r=0.876,P<0.01,^18F-FDG r=0.910,P<0.01);(3)^18F-FDG细胞结合抑制率与^18F-FLT细胞结合抑制率呈正相关(24h:r=0.657,P<0.01;48 h:r=0.432,P<0.05)。结论(1)^18F-FDG和^18F-FLT摄取变化可以早期评价5-Fu对肺腺癌A-549细胞的化疗疗效;随着5-Fu化疗时间的延长,肺腺癌A-549细胞摄取率下降更明显;(2)^18F-FDG和^18F-FLT相比,^18F-FDG细胞结合抑制率与^18F-FLT细胞结合抑制率呈正相关,且24 h较48 h相关性高;^18F-FLT早期摄取率与药物浓度的关系更密切,下降趋势更加明显,与MTT的关系更显著。因此,^18F-FLT联合^18F-FDG用于评价化疗疗效和指导用药将成为一种新的思路。 Objective To evaluate the effect of different concentrations of 5-Fu early by uptake of ^18F-FDG and ^18F-FLT in human lung adenocarcinoma A-549 cells. At the same time, to compare the two kinds of imaging agents preliminarily. Methods The proliferation inhibition effect by MTT and the uptake rates of ^18F-FDG and ^18F-FLT were detected after treatment with 5-Fu at 24 h and 48 h. Results (1)The uptake rates were negatively cor-related with the doses of 5-Fu at 24 h and 48 h after administration of 0.125, 0.25, 0.5 and 1.0 mg/mL 5-Fu (24 h:^18F-FLT r=-0.950, P〈0.01, ^18F-FDG r=-0.844, P〈0.01, 48 h: ^18F-FLT r=-0.939, P〈0.01, ^18F-FDG r=-0.786, P〈0.01) and the uptake rates of ^18F-FDG and ^18F-FLT with A-549 cells were lower at 48 h after administration of 5-Fu than at 24 h. (2)The binding inhibition efifciency was positively correlated with the proliferation inhibition (24 h: ^18F-FLT r=0.897, P〈0.01, ^18F-FDG r=0.978, P〈0.05, 48 h: ^18F-FLT r=0.876, P〈0.01, ^18F-FDG r=0.910,P〈0.01). (3)The binding inhibition efifciency of the two kinds of agents were correlated (24 h:r=0.657, P〈0.01, 48 h:r=0.432, P〈0.05). Conclusion (1)The study indicated that early therapeutic effect of 5-Fu for human lung adenocarcinoma A-549 cells could be assessed by ^18F-FDG and ^18F-FLT. (2)The binding efifciency of ^18F-FDG was more positive correlated with ^18F-FLT at 24 h than at 48 h. The relationship between early uptake rates and drug concentrations of ^18F-FLT were more closely, more pronounced downward and more signiifcantly correlated with MTT. Therefore, ^18F-FLT combined with ^18F-FDG could be used to evaluate the curative effect of chemotherapy and medication guide which will become a new way of thinking.
出处 《中国血液流变学杂志》 CAS 2013年第4期612-615,共4页 Chinese Journal of Hemorheology
关键词 ^18F-FDG ^18F-FLT 肺腺癌细胞 ^5-Fu ^18F-FDG ^18F-FLT lung adenocarcinoma cell 5-Fu
  • 相关文献

参考文献10

  • 1Duschinsky R, Pleven E, Heidelberger C. The Synthesis of 5-Fluoropyrimidines[J]. J Am Chem Soc, 1957, 79(16): 4559 - 4560.
  • 2于宏波,宋阳,马兴纲,齐红,席妍.MTT法测定复发转移性乳腺癌体外化疗药物敏感性实验研究[J].中国实验诊断学,2006,10(5):471-472. 被引量:6
  • 3谭业颖,田嘉禾,汤义军,张锦明,李善春,王朝阳,徐志英,林乐军.^(18)F-FLT与^(18)F-FDG评估化疗早期反应的细胞学研究[J].中国医学影像学杂志,2009,17(6):442-444. 被引量:3
  • 4Been LB, Suurmeijer AJ, Cobben DC, et al. [18F]FLT-PET in ontology: current status and opportunities[J]. Eur J Nucl Med Mol Imaging, 2004, 31(12): 1659 - 1672.
  • 5Pio BS, Park CK, Pietras R, et al. Usefulness of 3'-[F- 18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy[J]. Mol Imaging Biol, 2006, 8(1): 36 - 42.
  • 6魏荣卿,Machulla HJ,刘晓宁.检测肿瘤增殖的显像剂^(18)F-FLT[J].中华核医学杂志,2005,25(1):59-61. 被引量:5
  • 7Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies[J]. Nat Rev Cancer, 2003, 3(5): 330 - 338.
  • 8Barthel H, Cleij MC, Collingridge DR, et al. 3'-deoxy- 3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography[J]. Cancer Res, 2003, 63(13): 3791 - 3798.
  • 9Kornberg A, Baker TA. Biosynthesis of DNA precursors[A]. In: Kornberg A, Baker TA. DNA replication[M]. 2nd ed. New York: W.H. Freeman and Company Publ, 1992.53.
  • 10Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer[J]. Cancer Treat Rev, 2004, 30(2): 193 - 204.

二级参考文献45

  • 1辛华雯,王润帮,杜光祖,林鲁杰.十种常用抗癌药体外敏感性与临床疗效相关性研究[J].中国医院药学杂志,1994,14(12):548-550. 被引量:29
  • 2孙燕 周际昌.临床肿瘤内科手册[M].第3版[M].北京:人民卫生出版社,1996.30-34.
  • 3Been LB, Suurmeijer AJH, Cobben DCP, et al. [ ^18 F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging, 2004,31 : 1659.
  • 4Komberg A, Baker TA. Biosynthesis in DNA precursors. DNA replication. 2nd ed. New York W.H. Freeman,1992,53.
  • 5Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticaneer drug cisplatin. Science,1992,256:234.
  • 6Weber WA, Becker K, Dittler H J, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oneol, 2001,19:3058.
  • 7Haberkorn U, Bellemann ME, Brix G, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepaloma with gemeitabine. Eur J Nucl Med,2001,28 :418.
  • 8Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev,2004,30:193.
  • 9Burgman P, Odonoghue JA, Humm JL, et al. Hypoxia induced increase in FDG uptake in MCF7 cells. J Nucl Med,2001,42:170.
  • 10Karoline Spaepen, Sigrid Stroobants ,Patrick Dupont, et al. [ ^18F] FDG PET monitoring of tumour response to chemotherapy:does [ ^18F] FDG uptake correlate with the viable tnmour cell fraction? Eur J Nucl Med, 2003.30:682.

共引文献11

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部